Open, prospective study of the clinical efficacy of ciprofloxacin.
about
Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella InfectionsComparison of ofloxacin and ceftriaxone for short-course treatment of enteric feverIn vitro activities of tosufloxacin, temafloxacin, and A-56620 against pathogens of diarrhea.Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis.Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.Worldwide clinical data on efficacy and safety of ciprofloxacin.Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.Fluoroquinolones in the treatment of typhoid fever and the carrier state.How multidrug resistance in typhoid fever affects treatment options.Quinolones and the gastrointestinal tract.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.Overview of clinical experience with ciprofloxacin.Two-way and three-way approaches to ultra high performance liquid chromatography-photodiode array dataset for the quantitative resolution of a two-component mixture containing ciprofloxacin and ornidazole.Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection.In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureusFactors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.Comparison of two regimens for ciprofloxacin treatment of enteric infections.A relapse of paratyphoid fever after treatment with ciprofloxacin in a child with congenital biliary atresia.Salmonella typhi and other salmonellasSequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis.Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure.Clinical experience with ciprofloxacin in the USA.The place of quinolones in antibacterial therapy in hospitals.
P2860
Q28084595-09B5BBFF-24A1-43BB-80BF-E16AC7926E32Q33756339-37DCDB04-2C64-4684-8B5C-8A02B685698EQ35249168-9235C511-184B-4B88-952B-9638365DC1CAQ35253998-64449CB9-DB54-4703-AAF7-9E150A7AB802Q35353461-825618FA-8E96-4C49-9A1C-B113FE4103D6Q35536186-BBBF5AC4-65A3-4886-A50A-E0A2F1B3B395Q35547236-CE63D2A3-5585-4B93-A80F-B4B6EC237C6FQ35650708-2AF0C33F-3485-486B-8052-16486E7C312CQ36445457-B51FD5D2-B2D2-4BB4-B56A-199618B93AE4Q37222596-7CE40483-9485-4C34-9D87-F0557F74F051Q37222608-F7997DB0-8DF4-4C8E-AD0B-F3BA9D14B984Q38234712-4FC131A7-9575-46F6-B798-720F6E6C7D90Q38765030-2E1AD1D1-A234-48D9-A4D7-FF5FF5B4DC00Q39214819-CB93B54E-D2DC-4DFA-BC78-D441EAECEA08Q39502910-94D7433B-C634-44CC-A72B-07E47E5DEBD2Q39585784-F91C7ABE-0A5C-4230-9EE5-326EBED93DC6Q39730719-5C772832-AB8A-45C0-B617-674C5D6CC550Q39828223-45532849-3812-47A1-ABE8-EA8BBC038832Q39834459-B3322F05-6DCC-4D5A-8B40-C68B632103D8Q39834684-C5FF014D-92A6-459F-BDF2-D687D705D42DQ39850865-D00A2D4F-4961-4563-B233-9D4310B92A0BQ39851720-3F84DB5E-497E-4B22-9018-733CD61D2061Q40642870-B6A722F0-3EB3-49DF-88FD-FCE045C313B7Q40651412-DF7F4D13-1676-479F-960F-16DE5104ADA5Q40666346-206D8514-61B8-4634-A0E7-51237DD7938BQ43655616-8DE683D4-6A17-4391-9019-942B1AFB3514Q48159893-665901FB-065B-4588-8D09-CD082F3207CBQ50203682-CB0E91A7-AB18-4853-BB73-16487760036DQ54432495-988EDB28-F199-42A5-83C1-FBA49243FC3C
P2860
Open, prospective study of the clinical efficacy of ciprofloxacin.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Open, prospective study of the clinical efficacy of ciprofloxacin.
@ast
Open, prospective study of the clinical efficacy of ciprofloxacin.
@en
type
label
Open, prospective study of the clinical efficacy of ciprofloxacin.
@ast
Open, prospective study of the clinical efficacy of ciprofloxacin.
@en
prefLabel
Open, prospective study of the clinical efficacy of ciprofloxacin.
@ast
Open, prospective study of the clinical efficacy of ciprofloxacin.
@en
P2093
P2860
P356
P1476
Open, prospective study of the clinical efficacy of ciprofloxacin.
@en
P2093
P2860
P304
P356
10.1128/AAC.28.1.128
P407
P577
1985-07-01T00:00:00Z